Epstein-Barr nuclear antigen 1-specific CD4+ Th1 cells kill Burkitt's lymphoma cells

Journal of Immunology

Volumn 169, Issue 3, 2002, Pages 1593-1603

  Paludan, Casper ^a   Bickham, Kara ^a   Nikiforow, Sarah ^a   Tsang, Ming L ^a   Goodman, Kiera ^a   Hanekom, Willem A ^a   Fonteneau, Jean Francois ^a   Stevanović, Stefan ^a   Münz, Christian ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CELL NUCLEUS ANTIGEN; EPSTEIN BARR NUCLEAR ANTIGEN 1; GENE PRODUCT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; BURKITT LYMPHOMA; CARCINOGENESIS; CELL KILLING; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNITY; IMMUNOPATHOGENESIS; LYMPHOMA CELL; PRIORITY JOURNAL; TH1 CELL;

EID: 0036681812     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.169.3.1593     Document Type: Article

References (88)

1. Virus particles in cultured lymphoblasts from Burkitt's lymphoma
2. Morphological and biological studies on a virus in cultured lymphoblasts from Burkitt's lymphoma
3. A children's cancer dependent on climatic factors
4. Expression of Epstein-Barr virus-gene products in Burkitt's lymphoma in Northeast Brazil
5. A comparison of Epstein-Barr virus-specific T-cell immunity in malaria-endemic and -nonendemic regions of Papua New Guinea
6. HIV infection and neoplasia
7. Epstein-Barr virus-associated non-Hodgkin's lymphoma in patients infected with the human immunodeficiency virus
8. Acquired immunodeficiency syndrome-related lymphoma
9. Epstein-Barr virus and its replication
10. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell
11. Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes
12. Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell
13. EBV persistence in memory B cells in vivo
14. Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein, EBNA1, bound to DNA
15. Binding of EBNA-1 to DNA creates a protease-resistant domain that encompasses the DNA recognition and dimerization functions
16. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells
17. Three pathways of Epstein-Barr virus gene activation from EBNA1-posirive latency in B lymphocytes
18. Oncogenic role of Epstein-Barr virus-encoded RNAs in Burkitt's lymphoma cell line Akata
19. - RNA supports Burkitt's lymphoma growth through interleukin-10 induction
20. + T cell responses to EBV EBNA1: HLA class 1 presentation of the (Gly-Ala)-containing protein requires exogenous processing
21. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1
22. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1
23. Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory
24. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): Implications for the immune control of EBV-positive malignancies
25. Epstein-Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillance
26. Differentiation-dependent sensitivity of human B-cell-derived lines to major histocompatibility complex-restricted T-cell cytotoxicity
27. Herpes simplex virus turns off the TAP to evade host immunity
28. The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP
29. Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains
30. Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction
31. The human cytomegalovirus USI I gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol
32. + T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNAI
33. + T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function
34. Natural ligand motifs of closely related HLA-DR4 molecules predict features of rheumatoid arthritis associated peptides
35. Purification and characterization of class II histocompatibility antigens from a homozygous human B cell line
36. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids
37. An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics: EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection
38. Expression of Epstein-Barr virus nuclear antigen I is associated with enhanced expression of CD25 in the Hodgkin cell line L428
39. Differences between laboratory strains of Epstein-Barr virus based on immortalization, abortive infection and interference
40. + T-cell clones using peptide pulsed mature dendritic cells
41. Monoclonal antibodies directed against the Epstein-Barr virus-encoded nuclear antigen I (EBNA1): Immunohistologic detection of EBNA1 in the malignant cells of Hodgkin's disease
42. + interferon-γ-secreting, T lymphocytes
43. Two populations of la-like molecules on a human B cell line
44. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens: New tools for genetic analysis
45. Structural analysis of a human I-A homologue using a monoclonal antibody that recognizes an MB3-like specificity
46. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: Evidence for HLA-DM-independent processing
47. Cell phenotype dependent expression of MHC class 1 antigens in Burkitt's lymphoma cell lines
48. Inhibition of proteasomal degradation by the Gly-Ala repeat of Epstein-Barr virus is influenced by the length of the repeat and the strength of the degradation signal
49. + T cell recognition
50. Selective activation of Fas/Fas ligand-mediated cytotoxicity by a self peptide
51. +-ATPase, on CTL-mediated cytotoxicity
52. Concanamycin A. A powerful tool for characterization and estimation of contribution of perforin- and Fas-hased lytic pathways in cell-mediated cytotoxicity
53. Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: Evidence for their capacity to lyse autologous primary tumor cells
54. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr vires latent membrane protein-I: Coordinate up-regulation of peptide transporters and HLA-class I antigen expression
55. Mechanisms of allele-selective down-regulation of HLA class 1 in Burkitt's lymphoma
56. Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: Implications for cytotoxic T-lymphocyte control of EBV-associated malignancies
57. Transporter (TAP)-independent processing of a multiple membrane-spanning protein, the Epstein-Barr virus latent membrane protein 2
58. Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumor cell line
59. Immunization with tumor-associated epitopes fused to an endoplasmic reticulum translocation signal sequence affords protection against tumors with down-regulated expression of MHC and peptide transporters
60. Differential responses to CD40 ligation among Burkitt lymphoma lines that are uniformly responsive to Epstein-Barr virus latent membrane protein 1
61. + EBV-specific CTLs
62. Immune effector mechanisms in malaria
63. Is T-cell priming required for initiation of pathology in malaria infections?
64. T-cell control of Epstein-Barr virus-infected B cells is lost during P. falciparum malaria
65. Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study
66. Neonatal administration of IL-12 enhances the protective efficacy of antiviral vaccines
67. + T cell subsets during virus infection: Protective capacity depends on effector cytokine secretion and on migratory capability
68. Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells
69. B lymphocytes regulate dendritic cell (DC) function in vivo: Increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation
70. Antigen specific inhibition of effector T cell function in humans after injection of immature dendritic cells
71. + killer T cells
72. + T cell response: Lessons from the EBV nuclear antigen EBNA1
73. A role for B cells in the development of T cell helper function in a malaria infection in mice
74. Viral immune evasion due to persistence of activated T cells without effector function
75. + T cells
76. + T cell-mediated control of a γ-herpesvirus in B cell-deficient mice is mediated by IFN-γ
77. Regression of a murine γ herpesvirus 68-positive B-cell lymphoma mediated by CD4 T lymphocytes
78. + T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation
79. + memory T cell response to cytomegalovirus
80. + memory T cells display broad heterogeneity in their activation threshold for cytokine synthesis
81. + T-helper 1 responses
82. SYFPEITHI: Database for MHC ligands and peptide motifs
83. The major subtrates for TAP in vivo are derived from newly synthesized proteins
84. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes
85. Major histocompatibility complex class II-dependent unfolding, transport, and degradation of endogenous proteins
86. Cytoplasmic processing is a prerequisite for presentation of an endogenous antigen by major histocompatibility complex class II proteins
87. Processing pathways for presentation of cytosolic antigen to MHC class II-restricted T cells
88. Class II MCH molecules can use the endogenous pathway of antigen presentation